Made available by the elective open access option at the Journal of Commercial Biotechnology, this paper is free to view without subscription: The relevance and importance of business development and licensing in the biopharmaceutical industry Roger Davies Abstract The importance of the business development and licensing (BD&L) function in the global biopharmaceutical industry has grown significantly over the […]
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for July 30 2013
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for July 26 2013
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
August 8, 2013 Comments Off on Fostering the process of adoption of personalised medicine: A matter of communication or a matter of cost? Posted in: General Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Fostering the process of adoption of personalised medicine: A matter of communication or a matter of cost?
Go to paperABSTRACT: Pharmacogenetics, along with…
Like this:
Like Loading...
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Perhaps like me you are working and not on vacation this early August. If so, I hope that you will join me in a mental vacation to the Emerald […]
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for July 19 2013
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for July 23 2013
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
Drug Patent Expirations for July 2013
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
AZILECT
Teva
rasagiline mesylate
5,532,415
Jul 2, 2013
CIPRO
Bayer Hlthcare
ciprofloxacin
6,136,347*PED
Jul 6, 2013
EVOXAC
Daiichi Sankyo Co
cevi…
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for July 16 2013
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
This guest post is from the BiotechBlog Intern, Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. One of the more enduring financing trends in recent years has been to turn to public interest to help […]
Like this:
Like Loading...
